# BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

> **NCT07469774** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Biocity Biopharmaceutics Co., Ltd.** · enrollment: 111 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** BC3195
- **DRUG:** Pembrolizumab/KEYTRUDA®

## Key facts

- **NCT ID:** NCT07469774
- **Lead sponsor:** Biocity Biopharmaceutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 111 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07469774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07469774, "BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07469774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*